## 10-Year Financial / Non-Financial Data

(For the fiscal years as of / ended March 31)

	2008/3	2009/3	2010/3	
Net sales	1,128,875	980,803	883,086	
Selling, general and administrative (SG&A) expenses	396,678	418,558	347,125	
Percentage of net sales (%)	35.1%	42.7%	39.3%	
Percentage of net sales excluding R&D expenditures (%)	29.3%	35.5%	32.3%	
Operating income	112,826	42,722	61,160	
Percentage of net sales (%)	10.0%	4.4%	6.9%	
Ordinary income*1	97,312	25,679	46,075	
Net income (loss)	54,625	(50,561)	52,527	
Percentage of net sales (%)	4.8%	_	5.9%	
EBITDA margin*2 (%)	14.0%	12.8%	13.3%	
EBITDA margin (Medical Business)*3 (%)	31.1%	27.0%	29.2%	
R&D expenditures	65,928	70,010	61,850	
Percentage of net sales (%)	5.8%	7.1%	7.0%	
Capital expenditures*4	50,070	55,632	34,323	
Depreciation and amortization	37,497	44,594	43,099	
Amortization of goodwill	7,899	37,881	12,918	
Average exchange rate				
Yen / U.S. dollar	114.28	100.54	92.85	
Yen / Euro	161.53	143.48	131.15	
Financial indicators				
Total assets*5	1,217,172	1,038,253	1,104,528	
Total net assets*5	244,281	110,907	163,131	
Equity ratio (%)	19.1%	10.0%	14.1%	
Interest-bearing debt	656,756	642,839	661,481	
Net debt	533,475	505,763	454,698	
Inventories	110,379	95,540	89,959	
Inventory turnover period (months)	1.2	1.2	1.3	
Cash and cash equivalents at end of year	119,842	132,720	203,013	
Cash flows from operating activities	88,204	36,864	76,245	
Cash flows from investing activities	(274,104)	(15,964)	(20,967)	
Cash flows from financing activities	134,401	(3,751)	17,355	
Return on equity (ROE) (%)	24.4%	(30.2%)	40.6%	
Return on assets (ROA) (%)	9.3%	4.1%	4.9%	
Net income (loss) per share (yen)	202.11	(188.85)	194.90	
Total equity per share (yen)	861.58	387.31	576.63	
Price earnings ratio (PER) <sup>*6</sup> (times)	14.9	_	15.4	
Price book-value ratio (PBR) (times)	3.5	4.1	5.2	
Outstanding market value (billions of yen)	8,193	4,286	8,138	
Cash dividends per share (yen)	40	20	30	
Non-financial indicators				
Number of employees*7	35,772	36,503	35,376	
(Average number of temporary employees)	(—)	(—)	(—)	
Overseas employees as a percentage of employees (%)	65.4%	62.1%	63.3%	
Percentage of women in managerial roles*8 (%)	0.9%	0.8%	0.9%	
Percentage of employees with disabilities*9 (%)	1.6%	1.7%	1.8%	

\*1. Ordinary income is calculated using the following formula: Ordinary income = Operating income + Interest income - Interest expense ± Equity in gain (loss) of affiliates ± Other gains (losses) except for extraordinary gains (losses) defined in Japanese GAAP.

extractionization (conservence) delined in Separatese GAVA.
Ordinary guins (conservence) delined in Separatese GAVA.
Ordinary income is not presented in the consolidated statements of operations since the consolidated financial statements have been reformatted for the convenience of readers outside Japan as described in the notes to the financial statements.
\*2. At the Company, EBITDA is calculated using the following assumptions: EBITDA = Operating income + Depreciation and amortization that is included in Cost of sales or SG&A expenses + Amortization of goodwill that is included in SG&A expenses. EBITDA / Net sales
\*3. At the Company, EBITDA (Medical Business) is calculated using the following assumptions: EBITDA = Segment profit in the Medical Business + Depreciation and amortization that is included in cost of sales or SG&A expenses + Amortization that is included in Cost of sales or SG&A expenses + Amortization that is included in Cost of sales or SG&A expenses + Amortization that is included in Cost of sales or SG&A expenses + Amortization that is included in Cost of sales or SG&A expenses + Amortization that is included in Cost of sales or SG&A expenses + Amortization of goodwill that is included in SG&A expenses. EBITDA margin (Medical Business) = EBITDA (Medical Business) / Net sales

						Millions
2011/3	2012/3	2013/3	2014/3	2015/3	2016/3	2017/3
847,105	848,548	743,851	713,286	764,671	804,578	748,050
349,306	348,287	343,121	367,011	398,889	430,773	414,855
41.2%	41.0%	46.1%	51.5%	52.2%	53.5%	55.5%
33.3%	33.8%	37.6%	42.1%	42.5%	43.4%	44.9%
38,379	35,518	35,077	73,445	90,962	104,464	76,487
4.5%	4.2%	4.7%	10.3%	11.9%	13.0%	10.2%
23,215	17,865	13,046	50,913	72,782	90,898	62,149
3,866	(48,985)	8,020	13,627	(8,737)	62,594	78,191
0.5%	_	1.1%	1.9%	_	7.8%	10.5%
9.9%	9.5%	10.6%	16.8%	18.5%	19.2%	17.4%
26.9%	26.6%	29.0%	29.7%	29.1%	29.5%	27.4%
67,286	61,356	63,379	66,796	74,101	81,415	79,178
7.9%	7.2%	8.5%	9.4%	9.7%	10.1%	10.6%
32,699	37,961	28,109	37,810	47,743	64,445	49,347
34,188	33,787	33,899	36,850	41,219	39,912	44,658
11,619	11,103	9,683	9,457	9,421	9,867	8,642
85.72	79.08	83.10	100.24	109.93	120.14	108.38
113.12	108.98	107.14	134.37	138.77	132.58	118.79
1,019,160	966,526	960,239	1,027,475	1,081,551	1,000,614	991,062
115,579	48,028	151,907	331,284	357,254	384,283	430,880
11.0%	4.6%	15.5%	32.1%	32.9%	38.2%	43.3%
648,787	642,426	560,390	415,831	354,421	321,138	286,357
435,226	442,338	330,780	163,710	144,546	154,584	86,926
92,929	102,493	99,307	98,595	107,387	111,558	124,064
1.3	1.4	1.6	1.7	1.6	1.6	1.9
210,385	198,661	225,782	251,344	209,809	166,323	199,431
30,469	30,889	25,233	72,388	66,811	48,621	90,194
19,003	(35,735)	33,455	(20,273)	(39,612)	(52,897)	(8,305
(37,359)	(5,761)	(42,436)	(39,693)	(70,185)	(33,870)	(44,244
2.9%	(62.3%)	8.3%	5.7%	(2.6%)	17.0%	19.3%
0.4%	(4.9%)	0.8%	1.4%	(0.8%)	6.0%	7.9%
14.39	(183.54)	28.96	41.05	(25.53)	182.90	228.47
421.37	167.76	493.30	962.83	1,038.64	1,117.24	1,252.96
160.8	_	76.4	80.2	_	23.9	18.7
5.5	8.1	4.5	3.4	4.3	3.9	3.4
6,277	3,673	6,758	11,274	15,300	14,992	14,666
30		-		10	17	28
34,391	34,112	30,697	30,702	31,540	33,336	34,687
(5,336)	(5,009)	(2,240)	(2,978)	(1,374)	(1,257)	(1,298
62.4%	62.1%	62.4%	62.5%	63.2%	63.3%	63.7%
0.9%	0.8%	0.8%	1.1%	1.2%	1.2%	1.6%
1.8%	1.9%	1.9%	2.0%	2.1%	1.2%	2.1%

\*4. Capital expenditures are calculated based on the definition of capital expenditure in accordance with ASBJ Statement No. 17 "Accounting Standard for Disclosures about Segments of an Enterprise and Related Information."

and Heated Information."
"5. In line with the issuance of IAS No. 19 "Employee Benefits" (revised on June 16, 2011) to be applied for fiscal years beginning on or after January 1, 2013, certain overseas subsidiaries adopted IAS No. 19 effective from the fiscal year ended March 31, 2014, and changed their method of recognizing actuarial gain or loss. This change has been applied retroactively to the figures for the fiscal year ended March 31, 2014.

ended March 31, 2013. 6. Price earnings ratio (PER) for the fiscal years ended March 31, 2012 and 2015 are omitted as Olympus recorded net loss for these fiscal years. 7. The average number of temporary employees is stated in parentheses from the fiscal year ended March 31, 2011, as the number of temporary employees is over 10% of the total number of employees. 8. Figures for percentage of women in managerial roles only include individuals in Japan. 9. Figures for percentage of employees with disabilities are as of June 1 of the respective year and only include individuals in Japan.

(81)